Then, the pairwise comparison was used to analyze the NCF performances among the oligodendroglioma IDH-mutant (IDHm-O), astrocytoma IDH-mutant (IDHm-A) and astrocytoma IDH-wildtype (IDHwt-A) subgroups in patients with grade II glioma. The gene discussed is IDH1; the disease is central nervous system cancer.